Objective:To observe the changes of pathogenesis and Syk protein levels on mice of myasthenia gravis model through intravenous injection of iMDCs. Methods:Establish a mouse model of experimental autoimmune myasthenia graves(EAMG), using iMDCs’ intervention. Using 50 healthy male mice, they were randomly divided into model group A of 20 , the intervention group B of 20 and control group C of 10. From the primary immune to 90th day of termination of the experiment, clinical evaluation were undergone, and every group’s Syk protein levels of spleen and lymph nodes were examined and compared. Results: The incidence of clinical assessment:group A was higher than that in group B. At the end of the experiment the clinical score in two groups were 1.69 ± 1.12 and 0.35 ± 0.67 (P<0.01). Group C showed no disease. Syk protein expression levels of spleen and lymph nodes of A elevated compared with C mice (P<0.01), group B decreased compared with group A (P<0.05), but higher than that of group C (P<0.05). Conclusion:Intravenous injection of iMDCs can reduce the clinical symptoms of myasthenia gravis in mice and Syk protein expression, suggesting iMDCs can regulate immune disorders of EAMG.
experimental autoimmune myasthenia graves(EAMG)immature bone marrow dendritic cells(iMDCs)Syk protein
NETL
NSTL
万方数据
